Company intelligence / Profile preview
Glykos
Helsinki, Finlandglykos.fi ↗
- Ownership
- Private
- Employees
- ~11
- Development stage
- Other
01
Overview
Glykos is developing a pipeline of proprietary next-generation antibody-drug conjugates with enhanced therapeutic index, with its lead candidate GLK-33 in late preclinical development for CD33-positive hematologic cancers. Their ADCs utilize innovative linker and payload technology to improve tolerability and efficacy compared to previous-generation ADCs. Preclinical results indicate improved efficacy and safety over vedotin-based approaches.
- Therapeutic areas
- HematologyOncology
- Modalities
- Antibody-drug conjugateMonoclonal antibodySmall molecule
- Industry
- Biotech
02
Drug pipeline
5 assets4 more assets in the full pipeline.
03
Partnerships
Orion CorporationGenovis
Beyond the preview
Go deeper on Glykos.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Glykos.